Acuta Capital Partners, LLC Uni Qure N.V. Transaction History

Acuta Capital Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $2.16 Million - $2.86 Million	-60,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $315,420 - $474,179	7,000 Added 13.21%	60,000 $2.7 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $1.12 Million - $2.07 Million	28,000 Added 112.0%	53,000 $2.52 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $928,250 - $1.87 Million	25,000 New	25,000 $1.79 Million

141

33.7M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $237M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.